These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 25436806)
1. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806 [TBL] [Abstract][Full Text] [Related]
2. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics. Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691 [TBL] [Abstract][Full Text] [Related]
3. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203 [TBL] [Abstract][Full Text] [Related]
4. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement. Yoneshima Y; Okamoto I; Arimura-Omori M; Kimura S; Hidaka-Fujimoto N; Iwama E; Harada T; Takayama K; Nakanishi Y Invest New Drugs; 2015 Apr; 33(2):510-2. PubMed ID: 25433426 [TBL] [Abstract][Full Text] [Related]
5. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. O'Bryant CL; Wenger SD; Kim M; Thompson LA Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065 [TBL] [Abstract][Full Text] [Related]
6. Complex renal cysts associated with crizotinib treatment. Schnell P; Bartlett CH; Solomon BJ; Tassell V; Shaw AT; de Pas T; Lee SH; Lee GK; Tanaka K; Tan W; Tang Y; Wilner KD; Safferman A; Han JY Cancer Med; 2015 Jun; 4(6):887-96. PubMed ID: 25756473 [TBL] [Abstract][Full Text] [Related]
7. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib. Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366 [TBL] [Abstract][Full Text] [Related]
8. [Renal cysts - A novel complication of crizotinib treatment for lung cancer]. CsToth I; Meert AP; Sculier JP; Berghmans T Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699 [TBL] [Abstract][Full Text] [Related]
9. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551 [TBL] [Abstract][Full Text] [Related]
10. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Klempner SJ; Aubin G; Dash A; Ou SH Oncologist; 2014 Sep; 19(9):1008-10. PubMed ID: 25096999 [TBL] [Abstract][Full Text] [Related]
11. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Ou SH; Tong WP; Azada M; Siwak-Tapp C; Dy J; Stiber JA Cancer; 2013 Jun; 119(11):1969-75. PubMed ID: 23505007 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients. Cao Y; Xiao G; Qiu X; Ye S; Lin T PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361 [TBL] [Abstract][Full Text] [Related]
13. Crizotinib-induced pancreatic pseudocyst: a novel adverse event. Ishida H; Ichikawa W; Sasaki Y BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314 [TBL] [Abstract][Full Text] [Related]
14. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538 [TBL] [Abstract][Full Text] [Related]
15. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Dikopf A; Wood K; Salgia R Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177 [TBL] [Abstract][Full Text] [Related]